Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Spinal Cord ; 54(6): 423-30, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26439843

RESUMEN

STUDY DESIGN: Experimental study. OBJECTIVE: Several neuro-degenerative disorders such as Alzheimer's dementia, Parkinson's disease and amyotrophic lateral sclerosis (ALS) are associated with genetic mutations, and replacing or disrupting defective sequences might offer therapeutic benefits. Single gene delivery has so far failed to achieve significant clinical improvements in humans, leading to the advent of co-expression of multiple therapeutic genes. Co-transfection using two or more individual constructs might inadvertently result in disproportionate delivery of the products into the cells. To prevent this, and in order to rule out interference among the many promoters with varying strength, expressing multiple proteins in equimolar amounts can be achieved by linking open reading frames under the control of only one promoter. SETTING: Kazan, Russian Federation. METHODS: Here we describe a strategy for adeno-viral co-expression of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) interconnected through picorna-viral 2A-amino-acid sequence in transfected human umbilical cord blood mono-nuclear cells (hUCB-MCs). RESULTS: Presence of both growth factors, as well as absence of immune response to 2A-antigen, was demonstrated after 28-52 days. Following injection of hUCB-MCs into ALS transgenic mice, co-expression of VEGF and FGF2, as well as viable xeno-transplanted cells, were observed in the spinal cord after 1 month. CONCLUSION: These results suggest that recombinant adeno-virus containing 2A-sequences could serve as a promising alternative in regenerative medicine for the delivery of therapeutic molecules to treat neurodegenerative diseases, such as ALS.


Asunto(s)
Esclerosis Amiotrófica Lateral/terapia , Células Sanguíneas/metabolismo , Células Sanguíneas/trasplante , Cisteína Endopeptidasas/metabolismo , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo , Proteínas Virales/metabolismo , Adenoviridae/genética , Esclerosis Amiotrófica Lateral/genética , Animales , Cisteína Endopeptidasas/genética , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Sangre Fetal/citología , Factor 2 de Crecimiento de Fibroblastos/genética , Vectores Genéticos/fisiología , Células HEK293 , Humanos , Masculino , Ratones , Ratones Transgénicos , Mutación/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Superóxido Dismutasa-1/genética , Transfección , Factor A de Crecimiento Endotelial Vascular/genética , Proteínas Virales/genética
2.
Curr Mol Med ; 14(9): 1155-63, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24894167

RESUMEN

Some of the complexities of surgical interventions include neurological and psychiatric disturbances. Prompt identification and early treatment of these complications are pivotal in achieving excellent clinical results. Recognizing major adverse events such as stroke, seizure or delirium is usually straight-forward, however the discovery of less frequent or more subtle post-operative changes such as cognitive dysfunction might be delayed due to lack of appropriate diagnostic tools. This review summarizes biological markers that can be utilized as surrogates in evaluating surgery-related neuro-psychiatric disorders.


Asunto(s)
Procedimientos Quirúrgicos Cardíacos/efectos adversos , Trastornos del Conocimiento/metabolismo , Delirio/metabolismo , Cardiopatías/cirugía , Animales , Biomarcadores/metabolismo , Trastornos del Conocimiento/etiología , Delirio/etiología , Cardiopatías/metabolismo , Humanos , Periodo Perioperatorio , Factores de Riesgo
3.
Br J Pharmacol ; 169(4): 909-21, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23489026

RESUMEN

BACKGROUND AND PURPOSE: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a polyglutamine expansion in the huntingtin protein. We have previously demonstrated that the cell signalling of the metabotropic glutamate receptor 5 (mGluR5) is altered in a mouse model of HD. Although mGluR5-dependent protective pathways are more activated in HD neurons, intracellular Ca²âº release is also more pronounced, which could contribute to excitotoxicity. In the present study, we aim to investigate whether mGluR5 positive allosteric modulators (PAMs) could activate protective pathways without triggering high levels of Ca²âº release and be neuroprotective in HD. EXPERIMENTAL APPROACH: We performed a neuronal cell death assay to determine which drugs are neuroprotective, Western blot and Ca²âº release experiments to investigate the molecular mechanisms involved in this neuroprotection, and object recognition task to determine whether the tested drugs could ameliorate HD memory deficit. KEY RESULTS: We find that mGluR5 PAMs can protect striatal neurons from the excitotoxic neuronal cell death promoted by elevated concentrations of glutamate and NMDA. mGluR5 PAMs are capable of activating Akt without triggering increased intracellular Ca²âº concentration ([Ca²âº]i ); and Akt blockage leads to loss of PAM-mediated neuroprotection. Importantly, PAMs' potential as drugs that may be used to treat neurodegenerative diseases is highlighted by the neuroprotection exerted by mGluR5 PAMs on striatal neurons from a mouse model of HD, BACHD. Moreover, mGluR5 PAMs can activate neuroprotective pathways more robustly in BACHD mice and ameliorate HD memory deficit. CONCLUSIONS AND IMPLICATIONS: mGluR5 PAMs are potential drugs that may be used to treat neurodegenerative diseases, especially HD.


Asunto(s)
Enfermedad de Huntington/tratamiento farmacológico , Trastornos de la Memoria/prevención & control , Proteínas del Tejido Nervioso/agonistas , Fármacos Neuroprotectores/uso terapéutico , Nootrópicos/uso terapéutico , Receptor del Glutamato Metabotropico 5/agonistas , Regulación Alostérica/efectos de los fármacos , Animales , Conducta Animal/efectos de los fármacos , Muerte Celular/efectos de los fármacos , Células Cultivadas , Cuerpo Estriado/citología , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Embrión de Mamíferos/citología , Activación Enzimática/efectos de los fármacos , Proteína Huntingtina , Enfermedad de Huntington/metabolismo , Enfermedad de Huntington/fisiopatología , Trastornos de la Memoria/etiología , Ratones , Ratones Endogámicos , Ratones Transgénicos , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Neuronas/citología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Fármacos Neuroprotectores/efectos adversos , Fármacos Neuroprotectores/farmacología , Nootrópicos/efectos adversos , Nootrópicos/farmacología , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Fosforilación/efectos de los fármacos , Procesamiento Proteico-Postraduccional/efectos de los fármacos , Proteínas Proto-Oncogénicas c-akt/agonistas , Proteínas Proto-Oncogénicas c-akt/metabolismo , Receptor del Glutamato Metabotropico 5/metabolismo
4.
Curr Med Chem ; 18(7): 1019-37, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21254974

RESUMEN

Cognitive dysfunction following surgery is a common complication, which increases the incidence of other co-morbid conditions, hospital and health-care costs. The reported rate of the occurrence of post-operative cognitive decline varies with different studies, depending on population profile, type of surgery, definition of cognitive disorder and detection methods, design of study, etc. It remains unclear whether these psychiatric signs and symptoms are direct results of the effects of surgery or general anesthesia. Nonetheless they are more frequent after cardiac surgery and are likely to be multi-factorial, but the patho-mechanisms are not yet fully characterized. This communication provides a synopsis of proteomics tools and delineates novel SELDI-TOF results to evaluate biomarkers in this regard. Presented for the first time is a classification of the clinically relevant forms of post-operative cognitive decline with the advent of a novel subclass.


Asunto(s)
Líquido Cefalorraquídeo/química , Cognición/fisiología , Puente de Arteria Coronaria , Análisis por Matrices de Proteínas , Proteoma/análisis , Proteómica/métodos , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Animales , Humanos , Síndrome
5.
Curr Alzheimer Res ; 7(6): 556-63, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20455863

RESUMEN

BACKGROUND: Apolipoprotein-E (apoE) ε4 allele is a known risk factor for Alzheimer's disease (AD). Polymorphism of apoE is also one of the most important genetic markers for coronary artery disease (CAD). The allelic variation in the apoE gene has a significant effect on inter-individual variation of lipids and lipoprotein plasma levels as well. This study investigated whether apoE polymorphism affects the plasma levels of apoE and the possible association to CAD extent and cognitive functions. METHODS: Plasma apoE levels and apoE genotypes were evaluated of subjects with normal coronary arteries, and individuals with angiographycally confirmed mild/moderate or severe atheromatosis. The cognitive performance of the volunteers was also measured by mini-mental state examination (MMSE). RESULTS: Out of the 6 expected genotypes, only 5 were detected in participants: E3/3 (56.0%), E3/4 (23.6%), E4/4 (8.2%), E2/4 (3.3%), E2/3 (8.9%). The ε3 allele (72%) was the most frequent, followed by ε4 (22%) and ε2 (6%). No difference was found in plasma levels of either apoE or in apoE genotype frequencies among the groups, however MMSE scores of CAD patients irrespective of their atheromatosis extent were significantly lower than that seen in the normal population. CONCLUSIONS: Although neither apoE plasma levels, nor apoE polymorphism in patients presenting with mild/moderate or severe atheromatosis showed to be associated with CAD severity, the presence of atheromatosis in the heart vessels positively correlated with cognitive dysfunction.


Asunto(s)
Trastornos del Conocimiento/genética , Enfermedad de la Arteria Coronaria/genética , Placa Aterosclerótica/genética , Polimorfismo Genético/genética , Adulto , Anciano , Análisis de Varianza , Apolipoproteína E4/sangre , Apolipoproteína E4/genética , Trastornos del Conocimiento/sangre , Angiografía Coronaria/métodos , Enfermedad de la Arteria Coronaria/sangre , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Análisis Mutacional de ADN , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Lípidos/sangre , Lipoproteínas/sangre , Masculino , Escala del Estado Mental , Persona de Mediana Edad , Pruebas Neuropsicológicas , Placa Aterosclerótica/sangre , Placa Aterosclerótica/etiología
6.
Cell Mol Biol (Noisy-le-grand) ; 56 Suppl: OL1223-30, 2010 Feb 09.
Artículo en Inglés | MEDLINE | ID: mdl-20158975

RESUMEN

Studies revealed that the venom of the Brazilian "armed" spider Phoneutria nigriventer contains potent neurotoxins that caused excitatory symptoms such as salivation, lachrymation, priapism, convulsions, flaccid and spastic paralysis. It was also reported that the main mechanism of action of those neurotoxins are effects on ion channels such as inhibition of the inactivation of Na+ channels, blockage of K+ channels and blockage of calcium channels. The venom from Phoneutria keyserlingi, as might be expected, contains a series of polypeptides that are very similar, but not identical, to the proteins previously obtained from the venom of P. nigriventer in terms of their amino acid sequences and biological activities. We evaluated the effects of some of the toxins of P. nigriventer and P. keyserlingi on glutamate release and the decrease in [Ca2+]i by using synaptosomes of rat brain cortices and fluorimetric assays. Sequence comparisons between the Phoneutria toxins of both the species showed great similarity in the location of cysteine residues. However, thus far, no pharmacological assays were performed to evaluate the extension of those biochemical modifications. Our results showed that differences between the amino acid sequences of Phoneutria toxins of both the species lead to the significant changes in the pharmacological properties of these toxins.


Asunto(s)
Calcio/metabolismo , Ácido Glutámico/metabolismo , Venenos de Araña/farmacología , Sinaptosomas/metabolismo , Secuencia de Aminoácidos , Animales , Canales de Calcio/metabolismo , Fluorometría , Canales Iónicos/antagonistas & inhibidores , Canales Iónicos/metabolismo , Datos de Secuencia Molecular , Canales de Potasio/metabolismo , Ratas , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Canales de Sodio/metabolismo , Arañas/metabolismo
7.
Cell Mol Biol (Noisy-le-grand) ; 55 Suppl: OL1138-50, 2009 Aug 05.
Artículo en Inglés | MEDLINE | ID: mdl-19656467

RESUMEN

It has been suggested that overexpression of neuronal Ca2+ sensor-1 (NCS-1) protein is implicated in the pathophysiology of neurodisorders such as schizophrenia, bipolar disturbance and X-linked mental retardation. The mechanism by which NCS-1 would be involved in the causes and/or consequences of these neurodisorders is still far from elucidation. Independent evidence has pointed NCS-1 as a key regulator of synaptic efficacy by altering the expression and activity of voltage-gated channels, inhibiting internalization of dopaminergic receptors, and altering phosphoinositide metabolism. In this study, we examined the possible participation of NCS-1 protein in signal transmission dependent on muscarinic receptor activation, using PC12 cells stably expressing NCS-1 (PC12-NCS-1). Carbachol (CCH; 300 microM) was able to evoke glutamate release more efficiently from PC12-NCS-1 (15.3+/-1.0nmol/mg of protein) than wild type cells (PC12-wt; 8.3+/-0.9nmol/mg of protein). This increase of glutamate release induced by CCH was independent on extracellular Ca2+ influx. Additionally, a larger increase of cytoplasmic levels of InsP3 (663.0+/-63.0 and 310.0+/-39.0% of fluorescence in A.U.) and [Ca2+]i (766.4+/-40.0 and 687.8+/-37.1nmol/L) was observed after CCH stimulus of PC12-NCS-1 compared with PC12-wt. Clearly distinction between intracellular Ca2+ dynamics was also observed in PC12-NCS-1 and PC12-wt. A larger increase followed by fast decay of [Ca2+]i was observed in PC12-NCS-1. A plateau with a delayed decay of [Ca2+]i was characteristic of PC12-wt [Ca2+]i response. Both enhancement of InsP3 production and glutamate release observed in PC12-NCS-1 were blocked by atropine (10 microM). Together, our data show that overexpression of NCS-1 in PC12 cells induces an enhancement of intracellular second messenger and transmitter release dependent on CCH response, suggesting that muscarinic signaling is "up-regulated" in this cell model.


Asunto(s)
Ácido Glutámico/metabolismo , Proteínas Sensoras del Calcio Neuronal/fisiología , Neuropéptidos/fisiología , Receptores Muscarínicos/metabolismo , Transducción de Señal/fisiología , Animales , Calcio/metabolismo , Calcio/farmacología , Carbacol/farmacología , Quelantes/farmacología , Agonistas Colinérgicos/farmacología , Ácido Egtácico/análogos & derivados , Ácido Egtácico/farmacología , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/metabolismo , Microscopía Fluorescente , Proteínas Sensoras del Calcio Neuronal/genética , Proteínas Sensoras del Calcio Neuronal/metabolismo , Neuropéptidos/genética , Neuropéptidos/metabolismo , Células PC12 , Transporte de Proteínas/efectos de los fármacos , Ratas , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Transfección
8.
Cell Mol Neurobiol ; 27(1): 129-46, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17151945

RESUMEN

Various neurotoxins have been described from the venom of the Brazilian spider Phoneutria nigriventer, but little is known about the venoms of the other species of this genus. In the present work, we describe the purification and some structural and pharmacological features of a new toxin (PRTx3-7) from Phoneutria reidyi that causes flaccid paralysis in mice. The observed molecular mass (4627.26 Da) was in accordance with the calculated mass for the amidated form of the amino acid sequence (4627.08 Da). The presence of an alpha-amidated C-terminus was confirmed by MS/MS analysis of the C-terminal peptide, isolated after enzymatic digestion of the native protein with Glu-C endoproteinase. The purified protein was injected (intracerebro-ventricular) into mice at dose levels of 5 microg/mouse causing immediate agitation and clockwise gyration, followed by the gradual development of general flaccid paralysis. PRTx3-7 at 1 microM inhibited by 20% the KCl-induced increase on [Ca2+]i in rat brain synaptosomes. The HEK cells permanently expressing L, N, P/Q and R HVA Ca2+ channels were also used to better characterize the pharmacological features of PRTx3-7. To our surprise, PRTx3-7 shifted the voltage-dependence for activation towards hyperpolarized membrane potentials for L (-4 mV), P/Q (-8 mV) and R (-5 mV) type Ca2+ currents. In addition, the new toxin also affected the steady state of inactivation of L-, N- and P/Q-type Ca2+ currents.


Asunto(s)
Canales de Calcio/efectos de los fármacos , Activación del Canal Iónico/efectos de los fármacos , Venenos de Araña/farmacología , Secuencia de Aminoácidos , Animales , Canales de Calcio/genética , Canales de Calcio/fisiología , Células Cultivadas , Electrofisiología , Femenino , Humanos , Masculino , Ratones , Datos de Secuencia Molecular , Ratas , Ratas Wistar , Homología de Secuencia de Aminoácido , Venenos de Araña/química , Venenos de Araña/aislamiento & purificación , Arañas , Sinaptosomas/efectos de los fármacos , Transfección
9.
Neuroscience ; 139(2): 485-94, 2006 May 12.
Artículo en Inglés | MEDLINE | ID: mdl-16446040

RESUMEN

UNLABELLED: GABA is an important inhibitory transmitter in the CNS. In the enteric nervous system, however, both excitatory and inhibitory actions have been reported. Here, we investigated the effects of GABA on the intracellular Ca2+ concentration of guinea-pig myenteric neurons (at 35 degrees C) using Fura-2-AM. Neurons were identified by 75 mM K+ depolarization (5 s), which evoked a transient intracellular Ca2+ concentration increase. GABA (10 s) induced a dose dependent (5 nM-1 microM) transient intracellular Ca2+ concentration rise in the majority of neurons (500 nM GABA: 251+/-17 nM, n=232/289). Interestingly, the response to 5 microM GABA (n=18) lasted several minutes and did not fully recover. GABA response amplitudes were significantly (P<0.001) reduced by GABAA and GABAB receptor antagonists (10 microM) bicuculline and phaclofen. The GABAA agonist isoguvacine (10 microM) and GABAB agonist baclofen (10 microM) induced similar responses as 50 nM GABA, while the GABAC agonist cis-4-aminocrotonic acid (CACA) (10 microM) only elicited small responses in a minority of neurons. Removal of extracellular Ca2+ abolished all responses while depletion of intracellular Ca2+ stores by thapsigargin (5 microM) did not alter the responses to 500 nM GABA (n=13), but reduction of Ca2+ influx through voltage-dependent Ca2+ channels did. The nicotinic antagonist hexamethonium (100 microM) also reduced GABA responses by almost 70% suggesting that GABA stimulates cholinergic pathways, while the purinergic receptor blocker pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) and the 5-HT3 receptor blocker ondansetron only had minor effects. CONCLUSION: GABA elicits transient intracellular Ca2+ concentration responses in the majority of myenteric neurons through activation of GABAA and GABAB receptors and much of the response can be attributed to facilitation of ACh release. Thus GABA may act mainly as a modulator that sets the state of excitability of the enteric nerve network. A concentration of 5 microM GABA, although frequently used in pharmacological experiments, seems to cause a detrimental response reminiscent of the neurotoxic effects glutamate has in the CNS.


Asunto(s)
Acetilcolina/metabolismo , Calcio/metabolismo , Neuronas/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Ácido gamma-Aminobutírico/farmacología , Animales , Baclofeno/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Células Cultivadas , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Fura-2 , Agonistas del GABA/farmacología , Antagonistas del GABA/farmacología , Cobayas , Hexametonio/farmacología , Ácidos Isonicotínicos/farmacología , Plexo Mientérico/citología , Antagonistas Nicotínicos/farmacología , Ondansetrón/farmacología , Fosfato de Piridoxal/análogos & derivados , Fosfato de Piridoxal/farmacología , Antagonistas de la Serotonina/farmacología
10.
Neuroscience ; 101(1): 237-42, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11068152

RESUMEN

Glutamate is the major excitatory neurotransmitter in the CNS. The recent characterization of glutamate as a neurotransmitter in the enteric nervous system opened a new line of investigation concerning the role of glutamate in that system. The present study aimed to further characterize the enteric glutamate release and the calcium channels coupled to it. For this study the myenteric plexus-longitudinal muscle of guinea-pig ileum was stimulated with potassium chloride or with electrical pulses. The released glutamate was detected by spectrofluorimetry. Laser scanning confocal microscopy was used for analysis of immunolabeled enteric tissue for co-localization studies of calcium channels (N- and P/Q-type) and glutamate transporters (EAAC1). Here we report the effects of known Ca(2+)-channel blockers on glutamate release evoked by KCl-depolarization or electrical stimulation in the myenteric plexus. We find that N-type Ca(2+) channels control a major portion of evoked glutamate release from this system, with a very small contribution from L-type Ca(2+) channels. Moreover, alpha(1A)-like (P-type Ca(2+) channel) and alpha(1B)-like (N-type Ca(2+ )channel) immunoreactivity co-localized with glutamate transporters in the myenteric plexus. In addition, KCl-evoked or electrically stimulated glutamate release was sensitive to omega-agatoxin IVA, in a frequency-dependent manner, suggesting that P-type channels are also coupled to the release of glutamate. We, thus, conclude that both N-type and P-type Ca(2+) channels control most of the evoked glutamate release from the enteric nervous system, as also occurs in some parts of the CNS.


Asunto(s)
Sistema de Transporte de Aminoácidos X-AG , Canales de Calcio/efectos de los fármacos , Ácido Glutámico/metabolismo , Íleon/inervación , Potenciales de la Membrana/efectos de los fármacos , Plexo Mientérico/efectos de los fármacos , Neuronas/efectos de los fármacos , Simportadores , Animales , Anticuerpos/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio/clasificación , Canales de Calcio/metabolismo , Canales de Calcio Tipo L/efectos de los fármacos , Canales de Calcio Tipo L/metabolismo , Canales de Calcio Tipo N/efectos de los fármacos , Canales de Calcio Tipo N/metabolismo , Canales de Calcio Tipo P/efectos de los fármacos , Canales de Calcio Tipo P/metabolismo , Proteínas Portadoras/efectos de los fármacos , Proteínas Portadoras/metabolismo , Estimulación Eléctrica , Colorantes Fluorescentes/farmacología , Proteínas de Transporte de Glutamato en la Membrana Plasmática , Cobayas , Íleon/efectos de los fármacos , Íleon/metabolismo , Indoles/farmacología , Masculino , Potenciales de la Membrana/fisiología , Músculo Liso/efectos de los fármacos , Músculo Liso/inervación , Músculo Liso/metabolismo , Plexo Mientérico/citología , Plexo Mientérico/metabolismo , Neuronas/citología , Neuronas/metabolismo , Cloruro de Potasio/farmacología , Bloqueadores de los Canales de Sodio , Canales de Sodio/metabolismo , Tetrodotoxina/farmacología
11.
Neuroreport ; 11(10): 2191-4, 2000 Jul 14.
Artículo en Inglés | MEDLINE | ID: mdl-10923668

RESUMEN

Glutamate transporters are essential for the homeostasis of glutamate and normal function of glutamatergic synapses. Their function was shown to be regulated by redox agents and dimerizations that involves redox changes of cysteine residues. Peptide neurotoxins are also known to be rich in cysteine residues that contribute to their activity and stability. Among them is the toxin Tx3-4, from the spider Phoneutria nigriventer, which is able to inhibit glutamate uptake in rat hippocampal synaptosomes. Based on results obtained with manipulation of the redox state of cysteine residues in synaptosomes and in Tx3-4, we suggest that the effect of this toxin on glutamate uptake is due to interactions that involve cysteines both in the toxin and in the transporters.


Asunto(s)
Cisteína , Ácido Glutámico/metabolismo , Hipocampo/fisiología , Neuropéptidos/farmacología , Neurotoxinas/farmacología , Venenos de Araña/farmacología , Sinaptosomas/metabolismo , 4-Cloromercuribencenosulfonato/farmacología , Animales , Transporte Biológico/efectos de los fármacos , Ácido Ditionitrobenzoico/farmacología , Ditiotreitol , Oxidación-Reducción , Ratas , Ratas Wistar , Sinaptosomas/efectos de los fármacos
12.
Biochem J ; 343 Pt 2: 413-8, 1999 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-10510308

RESUMEN

Glutamate concentration increases significantly in the extracellular compartment during brain ischaemia and anoxia. This increase has an important Ca(2+)-independent component, which is due in part to the reversal of glutamate transporters of the plasma membrane of neurons and glia. The toxin phoneutriatoxin 3-4 (Tx3-4) from the spider Phoneutria nigriventer has been reported to decrease the evoked glutamate release from synaptosomes by inhibiting Ca(2+) entry via voltage-dependent Ca(2+) channels. However, we report here that Tx3-4 is also able to inhibit the uptake of glutamate by synaptosomes in a time-dependent manner and that this inhibition in turn leads to a decrease in the Ca(2+)-independent release of glutamate. No other polypeptide toxin so far described has this effect. Our results suggest that Tx3-4 can be a valuable tool in the investigation of function and dysfunction of glutamatergic neurotransmission in diseases such as ischaemia.


Asunto(s)
Ácido Glutámico/metabolismo , Neuropéptidos/farmacología , Neurotoxinas/farmacología , Péptidos/farmacología , Arañas , Sinaptosomas/efectos de los fármacos , omega-Conotoxinas , Transportadoras de Casetes de Unión a ATP/antagonistas & inhibidores , Transportadoras de Casetes de Unión a ATP/metabolismo , Sistema de Transporte de Aminoácidos X-AG , Animales , Unión Competitiva , Transporte Biológico/efectos de los fármacos , Calcio/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Relación Dosis-Respuesta a Droga , Ácido Egtácico/farmacología , Ácido Glutámico/farmacología , Hipocampo/citología , Cloruro de Potasio/antagonistas & inhibidores , Cloruro de Potasio/farmacología , Ratas , Ratas Wistar , Sinaptosomas/metabolismo , Veratridina/antagonistas & inhibidores , Veratridina/farmacología
13.
Int Orthop ; 16(2): 140-5, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1428312

RESUMEN

In a double-blind prospective randomised study we examined the effects of Diclofenac on heterotopic ossification after hip arthroplasty. Either the drug, or a placebo, was given by mouth to 158 patients in doses of 3 x 50 mg for 6 weeks. Diclofenac resulted in highly significant improvement (p less than 0.0001 versus controls) without severe side-effects. Heterotopic ossification decreased from 55% in the placebo to 15%. Significant degrees of heterotopic ossification did not occur with the drug. Movement of the hip was considerably increased after operation. We recommend Diclofenac prophylaxis against heterotopic ossification after hip operations in view of the serious clinical effects of this complication and its quoted incidence of 15% to 80%.


Asunto(s)
Diclofenaco/uso terapéutico , Prótesis de Cadera/efectos adversos , Osificación Heterotópica/prevención & control , Premedicación , Adulto , Anciano , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Osificación Heterotópica/tratamiento farmacológico , Estudios Prospectivos
14.
Int Orthop ; 15(2): 169-77, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1917195

RESUMEN

The osteogenic potential of bone and bone matrix has been characterised only by its biological effects and the parameters influencing it. Recently, the osteoinductive ability of bone matrix had been defined chemically by the description of a bone morphogenetic protein (BMP), and the parameters of osteogenic factors from different species have now been recognised. The current state of isolation, purification and characterisation of these factors is summarised in this review. General aspects of the isolation and testing of BMP preparations, and the results of orthotopic application of BMP implants, including clinical cases, are reported.


Asunto(s)
Sustancias de Crecimiento/fisiología , Osteogénesis , Proteínas/fisiología , Animales , Matriz Ósea/fisiología , Proteínas Morfogenéticas Óseas , Bovinos , Humanos , Proteínas/aislamiento & purificación , Especificidad de la Especie , Porcinos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...